Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Learn more about:
Related Clinical Trial
Tumor Grade Determines PD-1/PDL-1 Expression The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging To Assess and Compare the Performance Two Approach for Sentinel Lymph Node (SNLD) Biopsy for Endometrial Cancer Mindfulness in Endometrial and Cervical Cancer Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Colorectal, or Gastric Cancer Sentinel Node in Endometrial Cancer Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers. Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Effectiveness of Care in Certified Cancer Centres in Germany PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors Survivorship Promotion In Reducing IGF-1 Trial Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel Study of PF‑06940434 in Patients With Advanced or Metastatic Solid Tumors. Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients Gyn Onc Prehab Study Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers BP1001-A in Patients With Advanced or Recurrent Solid Tumors Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies Clinical Database and Biobank of Patients With Gynecologic Neoplasms Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Continuation of Follow-up of DES-Exposed Cohorts A Study of Patients Receiving High-Dose Rate Brachytherapy Effects of Centering Pre-operative Counseling on Patient Reported Anxiety Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer Exploring HIFU as a Treatment for Rectal and Other Pelvic Cancers Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies – (FIGHT-101) COM701 in Subjects With Advanced Solid Tumors A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors FPA150 in Patients With Advanced Solid Tumors Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function Carboplatin-cyclophosphamide Combined With Atezolizumab Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures. Study of Vaginal Dilator Use After Pelvic Radiotherapy Hula, a Physical Activity Intervention for Female-Cancer Survivors Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study Predictive Clinical and Biological Parameters in Gynecological Cancer – GC-BIO-IPC 2013-010 An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer Extended Follow-up of Columbia, MO Serum Bank Participants A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (TROPICS-03) Can the iKnife Distinguish Between Normal and Malignant Endometrial Tissue? Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study. Multiorgan Metabolic Imaging Response Assessment of Abemaciclib Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy Biomarkers for Gynecologic Cancer A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping Application of Tachosil During Lymphadenectomy Evaluation of Indocyanine Green-guided Systematic Pelvic Lymphadenectomy in Endometrial and Cervical Cancer Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer A Controlled Study of Quality of Life and it’s Related Factors Among Gynecological Cancer Survivors A Novel Tapered Applicator for Vaginal Vault Brachytherapy Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients Quality of Life in Survivors of Gynecologic Cancer PET-CT vs. Integrated MR-PET Scanning of GYN Cancers Endometrial Polyps: Pathophysiology and Clinical Consequences Radiation Therapy in Uterine Cancer: Dosimetry Analysis, Clinical Implication, and Survival Analysis A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy Targeted Disruption to Cancer Metabolism and Growth Through Dietary Macronutrient Modification Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells Trial of Maintenance With Niraparib- Uterine Serous Carcinoma CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors Bone Mineral Density and Subsequent Cancer Risk Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer Endometrial Changes in Breast Cancer Women With or Without Hormonal Therapies Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Cancer of the Uterus and Treatment of Stress Urinary Incontinence Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) Assessment of Screening Modalities for Gynecologic Cancers Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) Biomarker Guided Treatment in Gynaecological Cancer Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Tachosil for the Prevention of Symptomatic Lymph Cysts A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer Multimedia Aid Gynecologic Counseling and Consent Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study Translating Healthy Lifestyle Interventions for Cancer Survivors Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy? Screening for Endometrial Abnormalities in Overweight and Obese Women A Trial for Patients With Advanced/Recurrent Endometrial Cancer Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma Pembro/Carbo/Taxol in Endometrial Cancer Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Robot-assisted Laparoscopic Hysterectomy-RALH- Postoperative Complications, Quality of Life and Health Economics Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium Vaginal Cuff Brachytherapy Fractionation Study MK-3475 Immunotherapy in Endometrial Carcinoma Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer Anxiety and Distress Levels in Women With Suspected Endometrial Cancer Advanced Methods for Cancer Detection by Vaginal Screening END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer. Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 Quality of Life After Robotic Surgery for Endometrial Cancer SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma Pembrolizumab With Axitinib in Recurrent Endometrial Cancer A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Evaluation of Thiol Disulfide Balance in Stage 1 Endometrium Cancer Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] BEZ235 Trial in Patients With Advanced Endometrial Carcinoma Laparoscopic Approach to Cancer of the Endometrium Systematic Pelvic Lymphadenectomy Versus no Lymphadenectomy in Clinical Stage I-II Endometrial Cancer A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer Screening of Biomarkers on Endometrial Cancers Papillary Serous Carcinoma of the Endometrium Sentinel Node Biopsy in Endometrial Cancer ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers A Study to Assess the Efficacy and Safety of ABTL0812 Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma/Intraepithelial Neoplasia Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer Value of Diffusion Weighted Magnetic Resonance Imaging in Detection of Recurrent Disease in Surgically Treated Cervical and Endometrial Cancer Patients Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer) DOvEEgene: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy Exercise as an Intervention in Endometrial Cancer Survivors Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer Prevalence of Self Reported Lymphedema in Patients With Endometrial Cancer Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer Effect of Fertility-sparing Therapy of Early Endometrial Cancer Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Endometrial Cancer Conservative Treatment (E.C.Co). A Multicentre Archive Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer Different Risk Stratification Models for Prediction of Lymph Node Involvement in Endometrial Carcinoma ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer Lymphedema in Endometrial Cancer Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia High Intensity Interval Training in Endometrial Cancer A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer Hysteroscopic vs. Cervical Injection for Sentinel Node Detection of Endometrial Cancer Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer 3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients Sentinel Node Detection in Endometrial Cancer: A Consolidation Study on Detection Rates of Metastatic Disease Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients Cervical and Endometrial Injection for Sentinel Lymph Node Detection in Endometrial Cancer Disseminated Endometrial Cancer Cells During Sonohysterography Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer ENdometrial Cancer SURvivors’ Follow-up carE (ENSURE): Less is More? Pre-operative Studies for Prediction of Lymph Nodes Involvement in Endometrial Cancer Patients Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer Thunderbeat Technology vs Standard Bipolar Electro-surgery in Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for Endometrial Cancer Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer Endometrial Cancer – LOHP Alone and With 5FU Exemestane in Advanced and Recurrent Endometrial Carcinoma SLNM in Endometrial Cancer Combined With OSNA FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium the Effectiveness of a Weight Management Program in Patients Who Have Completed Treatment for Endometrial Cancer Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer Endometrial Cancer Biomarker Changes Following Exposure to Metformin Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer Role of Uterine Manipulator in Hysterectomy – Ro.Man.HY TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer Lifestyle Change and Quality of Life in Obese Patients With Stage I/II Endometrial Cancer in Remission Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO) Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Epidemiological Analysis on Endometrial Cancer in Guangdong Province of China Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer Prospective, Observational Study of Low-risk Criteria for Node Metastasis in Endometrial Cancer A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients. Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer Feasibility Study of Laparoendoscopic Single Site Surgical Staging for Endometrial Cancer Photoacoustic Endoscopy in Endometrial Cancer RAD001 in Recurrent Endometrial Cancer Patients Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer Psychosocial Benefits of Exercise in Endometrial Cancer Survivors Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC) Scale Down for Endometrial Cancer Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients GINECO-EN102b – BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer Intraoperative Pathological Evaluation for Surgical Treatment & Staging for Endometrial Cancer Patient’s Experience and Choice Between Investigations for Endometrial Cancer in Postmenopausal Bleeding Factors Affecting the Prognosis of Patients With Endometrial Cancer Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer 2D Versus 3D Radical Laparoscopic Hysterectomy for Endometrial Cancer: a Prospective Randomized Trial Risk Factors for Endometrial Cancer in Black Women Retrospective Study to Evaluate the Feasibility of Ovarian Preservation in Patients With Endometrial Carcinoma Sexual Functioning in Endometrial Cancer An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35 Molecular Staging of Endometrial Cancer Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer Sentinel Node Mapping in High Risk Endometrial Cancer Cytologic Analysis of Distention Media as a Screening Test for Endometrial Cancer Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer? Hysteroscopic Lymphatic Mapping for Endometrial Cancer Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer The Effects of the Endocrine System on Endometrial Cancer CT Assessment of BMI in Endometrial Cancer Patients MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers The Role of Functional MRI and Doppler Sonography in Assessing Blood Vessel Formation Within the Tumors of Endometrial Cancer Patients A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer Estrogen, Diet, Genetics and Endometrial Cancer A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) Pilot Study Using a PET Gamma Probe to Evaluate Lymph Nodes in Endometrial Cancer AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG Lymph Node Mapping in Patients With Endometrial Cancer Effect of Uterine Manipulator on Recurrence and Mortality of Endometrial Cancer Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom Racial Disparity in Endometrial Cancer Follow-up of Endometrial Cancer Patients Can Staging Magnetic Resonance Imaging (MRI) Features Prognosticate Patients Presenting With Endometrial Cancer? Endometrial Cancer Diet and Exercise Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients The DETECT Study: Discovery and Evaluation of Testing for Endometrial Cancer in Tampons Human Epididymis Protein 4 in Endometrial Carcinoma The Multicentic Trial in Fertility-sparing Treatment and Ovarian Preservation Management for Early Endometrial Cancer Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas Physical Activity After Endometrial Cancer Research of Circulating Tumor Cells Released During Endometrial Cancer Surgery. The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients Urinary miRNA in Endometrial Cancer Study Ketohexokinase Isoforms in Endometrial Cancer. PET/CT in the Management of Patients With Early Stage Endometrial Cancer Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer Telephone Follow-up After Treatment for Endometrial Cancer Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression HE4 is a Beneficial Biomarker in Endometrial Cancer Transvaginal Natural Orifice Endoscopic Surgery for Extremely Obese Patients With Early-stage Endometrial Cancer Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples

Brief Title

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Official Title

A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer

Brief Summary

      This is a phase 1/phase 2a study of the combination of immune checkpoint inhibitor
      (nivolumab) in combination with the PARP inhibitor (rucaparib) for patients with metastatic
      castration resistant prostate cancer (mCRPC) and metastatic/recurrent endometrial cancer.

      In the phase 1 portion, the safety of the combination dosing will be determined. If the
      combination dosing is determined to be safe and feasible, the study will move onto phase 2a.

      In the phase 2a portion, participants will be randomized to receive either: rucaparib alone,
      nivolumab alone, or combination therapy (rucaparib and nivolumab).
    


Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Dose limiting toxicities (DLT) rate of the combination of rucaparib and nivolumab (phase 1)

Secondary Outcome

 Time to disease progression in prostate cancer patients (phase 2)

Condition

Prostate Cancer

Intervention

Rucaparib

Study Arms / Comparison Groups

 Combination Therapy (Phase 1b Cohort)
Description:  Participants will receive rucaparib plus nivolumab in 4 week cycles.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

12

Start Date

August 14, 2018

Completion Date

December 2021

Primary Completion Date

February 29, 2020

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have the ability to understand and the willingness to signed a written
             informed consent document.

          -  Patients must have histologically or cytologically confirmed CRPC or endometrial
             cancer that is metastatic. Evidence of disease progression on a prior therapy is not
             required.

          -  Patients must have at least one lesion that is amenable to biopsy and the treating
             physician must deem this safe.

          -  Patient must be willing to undergo two mandatory research-only biopsies.

          -  Prostate cancer patients:

               -  Patients must be surgically or medically castrated, with serum testosterone
                  levels ≤ 50 ng/mL Patients being treated with Gonadotropin-releasing hormone
                  (GnRH) agonists must have such therapy continued throughout the study.

               -  Patients should have received at least one androgen receptor (AR)-targeted
                  therapy with abiraterone acetate or enzalutamide. Multiple lines of prior
                  AR-targeted therapy and chemotherapy are permitted. A washout of two weeks from
                  prior endocrine therapy (other than GnRH agonist); four weeks washout period from
                  prior cytotoxic chemotherapy or other anticancer agents is required (prior to day
                  1 of study therapy); six weeks washout period to allow for anti-androgen
                  withdrawal for patients managed with antiandrogen therapy such as bicalutamide.

          -  Endometrial cancer patients:

               -  An unlimited number of prior hormonal and/or chemotherapy regimens are permitted.
                  A washout of two weeks from prior endocrine therapy (other than GnRH agonist) and
                  four weeks from prior cytotoxic chemotherapy or other anticancer agents is
                  required (prior to day 1 of study therapy).

          -  At least 5 days should have elapsed since any non-study related minor surgical
             procedure and at least 21 days since any major surgical procedure prior to the first
             dose of rucaparib and the first dose of nivolumab.

          -  Must have an ability to swallow pills or capsules. Patients should have no current
             clinical evidence of bowel obstruction.

          -  Age must be ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status must be ≤ 1

          -  Patients must have normal hepatic, renal and marrow function as defined below:

               -  hemoglobin > 10 g/dL

               -  leukocytes ≥ 3,000/mcL

               -  absolute neutrophil count ≥ 1,500/mcL

               -  platelets ≥ 150,000/mcL

               -  total bilirubin within normal institutional limits

               -  alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 ×
                  institutional upper limit of normal

               -  creatinine within normal institutional limits OR creatinine clearance ≥ 60
                  mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

          -  Prior palliative radiotherapy must have been completed at least 2 weeks prior to first
             dose of study drug. Subjects with symptomatic tumor lesions at baseline that may
             require palliative radiotherapy within 4 weeks of first dose of study drug are
             strongly encouraged to receive palliative radiotherapy prior to enrollment.

          -  Reproductive Status: Rucaparib caused post-implantation loss (100% early resorptions)
             at all doses administered in an embryo-fetal development study. Based on its mechanism
             of action, nivolumab can cause fetal harm when administered to a pregnant woman.
             Pregnant women are therefore not eligible for this study.

               -  Women of child-bearing potential (WOCBP) must have a negative serum pregnancy
                  test result less than 3 days prior to administration of the first dose of
                  rucaparib.

               -  WOCBP must not be considering getting pregnant during the study.

               -  WOCBP and their male partners must agree to use a highly effective, reliable form
                  of contraception during treatment; for 6 months following the last dose of
                  rucaparib; and for at least 5 months following the last dose of nivolumab.

               -  Men who are sexually active with WOCBP must agree to use a highly effective,
                  reliable form of contraception during treatment; 6 months following the last dose
                  of rucaparib; and for a period of 7 months after the last dose of nivolumab .

               -  In addition to the above methods of contraception, use of a condom by male
                  patients is recommended to prevent transfer of drug through semen.

        Exclusion Criteria:

          -  Patients with active, known, or suspected autoimmune disease. Subjects with vitiligo,
             type I diabetes, mellitus, residual hypothyroidism due to autoimmune condition only
             requiring hormone replacement, psoriasis not requiring systemic treatment, childhood
             asthma that is not currently active, or conditions not expected to recur in the
             absence of an external trigger are permitted to enroll.

          -  Patients with a condition requiring systemic treatment with either corticosteroids (>
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration except for adrenal replacement steroid doses > 10 mg
             daily prednisone equivalent in the absence of active autoimmune disease. Note:
             Treatment with a short course of steroids (< 5 days) up to 7 days prior to initiating
             study drug is permitted.

          -  Patients who are receiving any other investigational agents.

          -  Prior exposure to PD-1 or PD-L1 inhibitors, other immune checkpoint inhibitors (e.g.
             anti-LAG-3, and anti-CTLA-4 antibodies), or PARP inhibitors.

          -  Patients with a "currently active" second invasive malignancy other than non-melanoma
             skin cancers. Patients are not considered to have a "currently active" malignancy if
             they have completed therapy and have been free of disease for ≥ 1 years.

          -  Patients with known and untreated or progressing brain metastases are excluded from
             this clinical trial because of their poor prognosis and because they often develop
             progressive neurologic dysfunction that would confound the evaluation of neurologic
             and other adverse events. Patients whose brain metastases have been treated with
             surgery and/or radiotherapy and are without evidence of progression on scan for at
             least 4 weeks, and are off steroids or antiseizure medications, will be eligible .

          -  Patients with symptomatic or impending spinal cord compression are not eligible unless
             appropriately treated.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to nivolumab or rucaparib.

          -  Based on in vitro CYP interaction studies, caution should be used for concomitant
             medications with a narrow therapeutic window that are substrates of CYP2C19, CYP2C9,
             and/or CYP3A. Selection of an alternate concomitant medication is recommended. Caution
             should also be exercised for concomitant use of certain statin drugs (e.g.
             rosuvastatin and fluvastatin) due to potential increase in exposure from inhibition of
             BCRP and CYP2C9. An updated list of clinically relevant P450 drug interactions (e.g:
             Flockhart Table http://medicine.iupui.edu/clinpharm/ddis/main-table/) should be
             reviewed while screening patients for study.

               -  Patients taking warfarin should have international normalized ration (INR)
                  monitored regularly according to standard institutional practices

               -  Because rucaparib is a moderate inhibitor of P-gp in vitro, caution should be
                  exercised for patients receiving rucaparib and requiring concomitant medication
                  with digoxin. Patients taking digoxin should have their digoxin levels monitored
                  after starting rucaparib and then regularly per standard clinical practice.

          -  Patients on parenteral nutrition are not eligible. Patients must not have a
             pre-existing duodenal stent or any gastrointestinal disorder or defect that would, in
             the opinion of the treating investigator, interfere with absorption of rucaparib.

          -  Uncontrolled intercurrent illness including, but not limited to, requirement for
             oxygen therapy, ongoing or active infection other than minor urinary tract infection,
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Known history of chronic hepatitis B or C as evidenced by:

               -  Positive test for hepatitis B surface antigen

               -  Positive test for qualitative hepatitis C viral load (by polymerase chain
                  reaction [PCR])

               -  Note: Subjects with positive hepatitis C antibody and negative quantitative
                  hepatitis C by polymerase chain reaction (PCR) are eligible.

          -  Human Immunodeficiency Virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             rucaparib. In addition, these patients are at increased risk of lethal infections when
             treated with marrow-suppressive therapy.

          -  Prior organ allograft or allogeneic bone marrow transplantation.

          -  Adverse effect of prior therapy not improved to Common Terminology Criteria for
             Adverse Events (CTCAE) Grade 1 or below with the exception of alopecia or lymphopenia.
             Ongoing Grade 2 non-hematologic toxicity (e.g. neuropathy) related to most recent
             treatment regimen may be permitted with prior advanced approval from the Lead
             Principal Investigator.

          -  Initiated denosumab or bisphosphonate therapy or adjusted denosumab or bisphosphonate
             dose/regimen within 4 weeks prior to first dose of rucaparib. Patients on a stable
             denosumab or bisphosphonate regimen are eligible and may continue treatment.

          -  Evidence or history of active or latent tuberculosis infection including purified
             protein derivative (PPD) recently converted to positive.

          -  Use of non-oncology vaccines containing live virus for prevention of infectious
             diseases within 12 weeks prior to study drug. The use of inactivated seasonal
             influenza vaccines, e.g., Fluzone®, will be permitted on study without restriction.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Walter Stadler, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03572478

Organization ID

IRB18-0154


Responsible Party

Sponsor

Study Sponsor

University of Chicago

Collaborators

 Bristol-Myers Squibb

Study Sponsor

Walter Stadler, MD, Principal Investigator, University of Chicago


Verification Date

May 2020